CANONICAL AND NONCANONICAL RTKs SIGNALING IN SOLID TUMOURS
DOI:
https://doi.org/10.52701/monc.2021.v2i2.37Keywords:
RTK, canonical, noncanonical, WNT, Hedgehog, Stat3, FGFR, cancerAbstract
Tumorigenesis is a multistep process that involves genetic and epigenetic alterations that accumulate over time and give rise to malignant cells. These cells have different attributes than a normal cell and are characterized by uncontrolled proliferation, invasion and resistance to apoptosis. Receptor tyrosine kinases are the target of many alterations that lead to malignant phenotype of the neoplastic cells and to cancer formation. The understanding of their role in cellular processes led to improved therapeutic schemes. Nonetheless, RTKs have intricate pathways that prove to be difficult to comprehend entirely and need further research in order to deliver an efficient therapeutical approach.
References
Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Medicinal research reviews. 2014;34(2):280-300. https://doi.org/10.1002/med.21288
Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Molecular cancer. 2018;17(1):1-13.
https://doi.org/10.1186/s12943-018-0782-4
Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity. International journal of oncology. 2017;51(5):1357-69. https://doi.org/10.3892/ijo.2017.4129
Koni M, Pinnarò V, Brizzi MF. The Wnt signalling pathway: a tailored target in cancer. International Journal of Molecular Sciences. 2020;21(20):7697. https://doi.org/10.3390/ijms21207697
Agostino M, Pohl SÖ-G. The structural biology of canonical Wnt signalling. Biochemical Society Transactions.2020;48(4):1765-80. https://doi.org/10.1042/BST20200243
Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434(7035):843-50.
https://doi.org/10.1038/nature03319
Xu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Molecular Cancer. 2020;19(1):1-35. https://doi.org/10.1186/s12943-020-01276-5
Katoh M. Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation. International journal of molecular medicine. 2018;42(2):713-25. https://doi.org/10.3892/ijmm.2018.3689
Yang Y, Zhou H, Zhang G, Xue X. Targeting the canonical Wnt/?-catenin pathway in cancer radioresistance: Updates on the molecular mechanisms. Journal of cancer research and therapeutics.2019;15(2):272. https://doi.org/10.4103/jcrt.JCRT_421_18
Jeng K-S, Sheen I, Leu C-M, Tseng P-H, Chang C-F. The role of smoothened in cancer. International Journal of Molecular Sciences. 2020;21(18):6863. https://doi.org/10.3390/ijms21186863
Pietrobono S, Gagliardi S, Stecca B. Non-canonical hedgehog signaling pathway in cancer: Activation of GLI transcription factors beyond smoothened. Frontiers in genetics. 2019;10:556.
https://doi.org/10.3389/fgene.2019.00556
Doheny D, Manore SG, Wong GL, Lo H-W. Hedgehog signaling and truncated GLI1 in cancer. Cells. 2020;9(9):2114.
https://doi.org/10.3390/cells9092114
Srivastava J, DiGiovanni J. Non?canonical Stat3 signaling in cancer. Molecular carcinogenesis. 2016;55(12):1889-98. https://doi.org/10.1002/mc.22438
Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Receptor tyrosine kinase-targeted cancer therapy. International journal of molecular sciences. 2018;19(11):3491. https://doi.org/10.3390/ijms19113491
Wu S-G, Shih J-Y. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. Molecular cancer. 2018;17(1):1-14. https://doi.org/10.1186/s12943-018-0777-1
Gul A, Rini BI. Adjuvant therapy in renal cell carcinoma. Cancer. 2019;125(17):2935-44.
https://doi.org/10.1002/cncr.32144
Moore S, Järvelin AI, Davis I, Bond GL, Castello A. Expanding horizons: new roles for non-canonical RNA-binding proteins in cancer. Current opinion in genetics & development. 2018;48:112-20.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Medico Science Press
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This work by Medico Science Press is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Medico Oncology is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute or share alike, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
